Dupilumab biosimilar (Jushi Biopharma)

度普利尤单抗生物类似药（石药集团巨石生物）

Report date: 2025/10/30 14:36:31

Base Information

Drug NameDupilumab biosimilar (Jushi Biopharma)
Drug Alias NameN/A
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-13 inhibitorsInterleukin-4 inhibitorsInterleukin-4 receptor subunit alpha inhibitors
TargetsInterleukin-13Interleukin-4Interleukin-4 receptor subunit alpha
Therapy Area/IndicationsDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJushi Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJushi Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A